MMR

Vertex Pharmaceuticals Incorporated (VRTX) Turns Up the Heat on Bears

Vertex Pharmaceuticals Incorporated's (VRTX) cystic fibrosis drug got the green light from the FDA

Jul 2, 2015 at 1:40 PM
facebook X logo linkedin


Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares shot higher today -- but are currently halted at $130.90 -- on news that the company's cystic fibrosis therapy, Orkambi, received Food and Drug Administration (FDA) approval. With its intraday lead approaching 4%, the stock has advanced 32.5% year-over-year -- though it's struggled in recent months in the $130-$133 neighborhood. Amid this recent churn, option traders have gravitated toward long puts.

Diving right in, during the last 10 days at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 1.36 puts for every call. This ratio ranks in the 82nd percentile of its annual range, suggesting traders have bought to open puts over calls at a faster-than-usual pace lately.

Further reflecting this bias toward puts is VRTX's Schaeffer's put/call open interest ratio (SOIR) of 1.31. Not only does this SOIR indicate short-term put open interest outweighs call open interest, but it also rests above 79% of comparable readings from the previous 12 months.

Analysts are tilted in a skeptical direction, as well. Over half of the brokerages covering Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have doled out tepid "hold" ratings. What's more, the stock's average 12-month price target of $140.10 is just 7% above the current perch -- though it does represent uncharted territory for VRTX.
 

AI has exploded ever since ChatGPT set the world on fire near the end of 2022.

Numerous companies with connections to artificial intelligence have seen their stocks soar.

That includes Nvidia, the poster boy of AI.

Its stock has skyrocketed 716% since ChatGPT’s debut. But here’s the thing …

While everyone’s still counting their money from this first AI boom … Nvidia and countless others have moved on to the next stage.

That includes Big Tech, which is currently making a series of peculiar investments in a few strange companies. This has nothing to do with tech. At least on the surface …

Yet, these strange investments could be the early ripples of a massive wave …Without them, ChatGPT could stop operating … Amazon, Google, Microsoft and more could see profits drop drastically.

In fact, Elon Musk says these investments are critical when it comes to solving the number one problem facing AI.

Now, Silicon Valley legend Michael Robinson has identified two companies that could play a significant role in the solution.

Their stocks just may be the key to AI 2.0.

Find out more about these two companies today.
 (ad)